Abacavir/lamivudine/zidovudine

Abacavir/lamivudine/zidovudine, sold under the trade name Trizivir, is a medication for HIV infection.[1] It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:[2]

Abacavir/lamivudine/zidovudine
Combination of
AbacavirNucleoside analogue reverse transcriptase inhibitor
LamivudineNucleoside analogue reverse transcriptase inhibitor
ZidovudineNucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade namesTrizivir
AHFS/Drugs.comFDA Professional Drug Information
MedlinePlusa687007
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Oral
    ATC code
    Legal status
    Legal status
    Identifiers
    CAS Number
    ChemSpider
    KEGG
    NIAID ChemDB
     NY (what is this?)  (verify)

    It is indicated in the treatment of AIDS/HIV.[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[4]

    The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.

    In December 2013, Lupin Limited launched a generic version of Trizivir.[5][6] As of 2016 the wholesale cost for a typical month of medication in the United States is more than 669.30 USD.[7]

    See also

    References
    1. Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean‐Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc (May 2002). "A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection". The Journal of Infectious Diseases. 185 (9): 1251–1260. doi:10.1086/340312. PMID 12001042.
    2. InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture Archived January 4, 2012, at the Wayback Machine
    3. Drugs.com: Trizivir
    4. Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". Cochrane Database Syst Rev (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMID 19160297.
    5. Monthly Prescribing Reference (MPR)
    6. Lupin Pharma
    7. "NADAC as of 2016-12-07 | Data.Medicaid.gov". Centers for Medicare and Medicaid Services. Retrieved 12 December 2016.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.